CN1139379C - Carbocisteine composition for promoting healing of wound and burn - Google Patents
Carbocisteine composition for promoting healing of wound and burn Download PDFInfo
- Publication number
- CN1139379C CN1139379C CNB001034871A CN00103487A CN1139379C CN 1139379 C CN1139379 C CN 1139379C CN B001034871 A CNB001034871 A CN B001034871A CN 00103487 A CN00103487 A CN 00103487A CN 1139379 C CN1139379 C CN 1139379C
- Authority
- CN
- China
- Prior art keywords
- wound
- burn
- carbocisteine
- composition
- wounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a carbocistein composition for accelerating the healing of wounds and burn, which is prepared from carbocistein, sodium citrate, sodium dodecyl sulfate, magnesium dodecyl sulfate and sodium deoxycholate through mixing, heating, stirring, cooling, grinding, remixing and restirring. The composition capable of being combined with any medicinal carrier capable of being applied to the wounds in the field has the advantages of rapid stabilization of the wounds and the burn, effective shortening of wound time, promption of the rapid and natural healing of the wounds and the burn, and scar hyperplasia rate reduction. The composition can also be used for the transplantation of the skin to enhance the survival property of a transplanted object in a target position in a host bed.
Description
The present invention relates to the carbocisteine compositions of a kind of acceleration of wound and burn-healing, relate to specifically a kind ofly be prepared from by carbocisteine and cell induction agent, can stablize wound and burn rapidly, quicken the compositions of its healing, have another name called compositions for Carbocisteine.
At present, wound and burn are a kind of common disease of surgery medical science on clinical medicine.The generally acknowledging principle that its wound surface is handled is: remove slough, the protection wound surface is protected from infection, and promotes epithelial cell growth.Yet prior treatment method still rests on the outmoded level of anti-inflammation, generally is to adopt silver sulfadiazine, to keep the wound surface drying, protects from infection.This medicine can not prevent the pathological change (body fluid oozes out, and nutritional labeling is lost, the evaporation of heat etc.) of burn wound, can not promote epithelial cell growth effectively.Certain anti-infectious function can only be played, the situation of traumatic infection can not be eliminated and thoroughly change fully.Moreover the existing antibacterial-anti-inflammatory drug that is used for wound and burn can not play to be accelerated wound healing and shortens the wound time, so how could stablize wound and burn rapidly, quickening its healing is the focus that the relevant person pays close attention to.
The object of the present invention is to provide a kind ofly to be prepared from, can stablize wound and burn rapidly, shorten the acceleration of wound of wound time and the carbocisteine compositions of burn-healing by carbocisteine and cell induction agent.
The object of the present invention is achieved like this: it is made up of carbocisteine and cell induction agent sodium citrate, sodium lauryl sulphate, Stepanol MG, NaTDC, form through grinding, sieve, mix, stirring, it is characterized in that it is the compositions of being made by following weight (g) proportion raw material:
Carbocisteine 0.1-8.0
Sodium citrate 1.0-5.0
Sodium lauryl sulphate 1.0-3.0
Stepanol MG 1.0-3.0
NaTDC 1.0-3.0.
Its feature is that also it is the compositions of preferred following weight (g) proportion raw material preparation:
Carbocisteine 1.5
Sodium citrate 1.0-5.0
Sodium lauryl sulphate 1.5
Stepanol MG 1.0-3.0
NaTDC 1.0-3.0.
Its feature also is: the granule of described carbocisteine≤70 micron.
Its feature also is: described cell induction agent is sodium citrate, sodium lauryl sulphate, Stepanol MG and NaTDC, but also wherein one or more.
The present invention compared with prior art, it can combine with any pharmaceutical carrier that can be applicable to wound in this area, can stablize wound and burn rapidly, effectively shorten the wound time, impel wound and burn normal healing rapidly, reduce the scar hyperplasia rate, the transplanting that it also can be used for skin strengthens the one-tenth activity of transplanted thing destination locations in host's bed.
Embodiment one
Abdominal part is scalded dark II degree wound surface, adopts general wound Drug therapy, around be the course of treatment; Select for use the present invention by 70 micron granularity carbocisteine 1.5g, with the cell induction agent: the compositions that sodium citrate 1.0g, sodium lauryl sulphate 1.5g, Stepanol MG 1.5g, NaTDC 1.5g become through conventional method processing and preparing such as grinding, mixing, stirrings, have another name called compositions for Carbocisteine, on spreading and the wound face, contact processing, two weeks can heal, and had significantly shortened the wound time, had alleviated patient's misery.
Embodiment two
Diabetes finger tip ulcer adopts general medicine for ulcer treatment, needs for 15 weeks the course of treatment; Select for use the present invention by 70 micron granularity carbocisteine 1.5g, with the cell induction agent: the compositions that sodium citrate 0.8g, sodium lauryl sulphate 1.5g, Stepanol MG 1.6g, NaTDC 1.3g become through conventional method processing and preparing such as grinding, mixing, stirrings, have another name called compositions for Carbocisteine, on spreading and the wound face, contact processing, ten weeks can heal, and had significantly shortened the wound time, had alleviated patient's misery.
Claims (3)
1, the pharmaceutical composition of a kind of acceleration of wound and burn-healing, it contains the form combination of carbocisteine chemical compound and cell induction agent, it is characterized in that it is the compositions of being made by following weight (g) proportion raw material:
Carbocisteine 0.1-8.0
Sodium citrate 1.0-5.0
Sodium lauryl sulphate 1.0-3.0
Stepanol MG 1.0-3.0
NaTDC 1.0-3.0
2, the pharmaceutical composition of claim 1 is characterized in that described cell induction agent can be sodium lauryl sulphate, sodium citrate, Stepanol MG and NaTDC.Also can compatibility wherein one or more.
3, the pharmaceutical composition of claim 1, its feature also are to combine with treating compatible pharmaceutical carrier, are prepared into the active drug that wound is burnt in treatment.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB001034871A CN1139379C (en) | 2000-03-15 | 2000-03-15 | Carbocisteine composition for promoting healing of wound and burn |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB001034871A CN1139379C (en) | 2000-03-15 | 2000-03-15 | Carbocisteine composition for promoting healing of wound and burn |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1266681A CN1266681A (en) | 2000-09-20 |
| CN1139379C true CN1139379C (en) | 2004-02-25 |
Family
ID=4577022
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB001034871A Expired - Fee Related CN1139379C (en) | 2000-03-15 | 2000-03-15 | Carbocisteine composition for promoting healing of wound and burn |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1139379C (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3081212A1 (en) | 2015-04-16 | 2016-10-19 | Polichem SA | Carboxymethylcysteine for topical treatment of stretch marks |
| WO2023126161A1 (en) * | 2021-12-31 | 2023-07-06 | Unilever Ip Holdings B.V. | A personal care or pharmaceutical composition |
| CN114366731A (en) * | 2022-02-10 | 2022-04-19 | 王有仁 | Application of carboxymethyl cysteine crystal in preparation of enzyme activity activator |
-
2000
- 2000-03-15 CN CNB001034871A patent/CN1139379C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1266681A (en) | 2000-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Klasen | Historical review of the use of silver in the treatment of burns. I. Early uses | |
| Yang et al. | Zinc-nutrient element based alloys for absorbable wound closure devices fabrication: current status, challenges, and future prospects | |
| WO2015096271A1 (en) | High strength and toughness corrosion-resistant zinc alloy inplant material capable of being absorbed by human body | |
| Tiemann et al. | Principles of the therapy of bone infections in adult extremities: Are there any new developments? | |
| Hooley et al. | The effect of polylactic acid granules on the incidence of alveolar osteitis after mandibular third molar surgery: A prospective randomized study | |
| CN1139379C (en) | Carbocisteine composition for promoting healing of wound and burn | |
| CN108578540A (en) | A kind of biologic formulation and preparation method thereof for inhibiting scar and promoting wound healing | |
| Kumar et al. | Collagen membrane: A new concept in surgical management for mucosal defect in oral sub mucous fibrosis. | |
| CN106562953B (en) | Application, drug and process for preparing medicine of the hydroxyl radical carthamin yellow carthamus A in the drug of preparation treatment diabetic foot ulcer | |
| CN102028875B (en) | Medicament for treating open wound and preparation method thereof | |
| Melamed et al. | Anterior Ankle Full Thickness Skin Necrosis Treated with Copper Oxide Dressings without Debridement and Skin Grafting–A Case Report | |
| Aksakal et al. | Decompression for the management of onychocryptosis | |
| CN101647952A (en) | Flesh engendering and wound closing medicament for external use | |
| Adornato et al. | Hemostatic technique using a splint in oral bleeding | |
| Ragab et al. | Comparison of two hemostatic agents in patients receiving anticoagulants without altering medication dosage | |
| CN108392572A (en) | A kind of plaster and its preparation method and application that expelling the stasis for the new sore relieves the pain | |
| CN106668062A (en) | Medicinal composition, application of medicinal composition to preparation of medicament for wound healing, medical preparation and medical bandage | |
| CN109803726A (en) | Wound healing agent with antibiotic property and promotion wound healing | |
| CN101869578B (en) | External liniment for drawing pus out and diminishing inflammation | |
| Zaveri | Surgical management of surgical site infections in orthopaedics | |
| CN1044778C (en) | Suppurative wound treating medicine for domestic animal | |
| Jin | Design of an Antibacterial Bio-adhesive Material with Silver Nanoparticles | |
| Jamil et al. | Authenticity of zinc oxide nanoparticles and zinc oxide playing vital role in wound healing | |
| RU2182490C1 (en) | Composition of biostimulating and antitoxic action | |
| Gulnora | Efficiency in phytotherapy endogenous intoxication syndrome in pregnant women with infectious risk |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: Wang Youren Document name: Notification to Pay the Fees |
|
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: Wang Youren Document name: Notification of Termination of Patent Right |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20040225 Termination date: 20180315 |